[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing University of Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,76,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100053374","fuyang-jiedu-granules-plus-antiretroviral-therapy-for-hiv-immune-non-responders-with-spleen-kidney-yang-deficiency-100053374",false,"NCT07698548","Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency","A Pragmatic Randomized Controlled Trial of Fuyang Jiedu Granules Combined With Antiretroviral Therapy for Immune Reconstitution Failure in People With HIV and Spleen-Kidney Yang Deficiency Syndrome","FYJD-INR-pRCT","Inclusion Criteria:Aged 18 to 60 years, male or female. CD4+ T lymphocyte count \\\u003C350 cells\u002FuL. Meets diagnostic criteria for HIV-1 infection according to the Chinese Guidelines for Diagnosis and Treatment of HIV\u002FAIDS (2024 edition).\n\nMeets diagnostic criteria for incomplete immune reconstitution: ART for more than 4 years; peripheral blood viral load below the lower limit of detection (\\\u003C50 copies\u002FmL) for more than 3 years; persistent CD4+ T-cell count \\\u003C350 cells\u002FuL; and exclusion of other causes of long-term low CD4+ T-cell count.\n\nMeets the Traditional Chinese Medicine diagnostic criteria for spleen-kidney yang deficiency syndrome, supported by the designated four-diagnostic instrument (model SZY-ZM-1) where applicable.\n\nVoluntarily agrees to participate and signs informed consent. -\n\nExclusion Criteria:Uncontrolled acute or chronic physical or mental illness. Poor adherence to ART. WBC \\\u003C2 x 10\\^9\u002FL, neutrophils \\\u003C1.0 x 10\\^9\u002FL, hemoglobin \\\u003C90 g\u002FL, platelets \\\u003C75 x 10\\^9\u002FL, or abnormal hepatic\u002Frenal function. Hepatic abnormality is defined as AST, ALT, or total bilirubin \\>=2 times the upper limit of normal; renal abnormality is defined as creatinine clearance below the normal value.\n\nOther serious comorbid disease, such as tumor, cirrhosis, or cardiovascular\u002Fcerebrovascular disease.\n\nPregnancy, lactation, or recent plan for pregnancy\u002Fchildbearing. Use of immunosuppressants or immunomodulators within 6 months before screening. Any other condition judged by the investigator to make the participant unsuitable for the study.\n\n\\-","ALL","18 Years","60 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and spleen-kidney yang deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Fuyang Jiedu Granules plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.",[28,29,30,31,32],"HIV-1 Infection","Acquired Immunodeficiency Syndrome","Immune Reconstitution Failure","Immunological Non-responder","Spleen-Kidney Yang Deficiency Syndrome",[34,35,36,37,38,39,40,41,42,43],"HIV","AIDS","immune non-responder","incomplete immune reconstitution","ART","CD4+ T cell","Traditional Chinese Medicine","Fuyang Jiedu Granules","pragmatic randomized controlled trial","pRCT","NOT_YET_RECRUITING","2026-07-07",{"date":47,"type":48},"2026-07-13","ACTUAL",{"date":50,"type":22},"2026-08",{"date":52,"type":22},"2029-02",{"name":54,"class":55},"Beijing University of Chinese Medicine","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":75,"locationsCount":56},"100053530","qiling-yiqi-tablets-plus-antiretroviral-therapy-for-hiv-immune-non-responders-with-lung-spleen-qi-deficiency-100053530","NCT07698574","Qiling Yiqi Tablets Plus Antiretroviral Therapy for HIV Immune Non-responders With Lung-Spleen Qi Deficiency","A Pragmatic Randomized Controlled Trial of Qiling Yiqi Tablets Combined With Antiretroviral Therapy for Immune Reconstitution Failure in People With HIV and Lung-Spleen Qi Deficiency Syndrome","QLYQ-INR-pRCT","Inclusion Criteria:Aged 18 to 60 years, male or female. CD4+ T lymphocyte count \\\u003C350 cells\u002FuL. Meets diagnostic criteria for HIV-1 infection according to the Chinese Guidelines for Diagnosis and Treatment of HIV\u002FAIDS (2024 edition).\n\nMeets diagnostic criteria for incomplete immune reconstitution: ART for more than 4 years; peripheral blood viral load below the lower limit of detection (\\\u003C50 copies\u002FmL) for more than 3 years; persistent CD4+ T-cell count \\\u003C350 cells\u002FuL; and exclusion of other causes of long-term low CD4+ T-cell count.\n\nMeets the Traditional Chinese Medicine diagnostic criteria for lung-spleen qi deficiency syndrome, supported by the designated four-diagnostic instrument (model SZY-ZM-1) where applicable.\n\nVoluntarily agrees to participate and signs informed consent. -\n\nExclusion Criteria:Uncontrolled acute or chronic physical or mental illness. Poor adherence to ART. WBC \\\u003C2 x 10\\^9\u002FL, neutrophils \\\u003C1.0 x 10\\^9\u002FL, hemoglobin \\\u003C90 g\u002FL, platelets \\\u003C75 x 10\\^9\u002FL, or abnormal hepatic\u002Frenal function. Hepatic abnormality is defined as AST, ALT, or total bilirubin \\>=2 times the upper limit of normal; renal abnormality is defined as creatinine clearance below the normal value.\n\nOther serious comorbid disease, such as tumor, cirrhosis, or cardiovascular\u002Fcerebrovascular disease.\n\nPregnancy, lactation, or recent plan for pregnancy\u002Fchildbearing. Use of immunosuppressants or immunomodulators within 6 months before screening. Any other condition judged by the investigator to make the participant unsuitable for the study.\n\n\\-",{"count":21,"type":22},[25],"This pragmatic randomized controlled trial evaluates whether Qiling Yiqi Tablets combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and lung-spleen qi deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Qiling Yiqi Tablets plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.",[28,29,30,31,69],"Lung-Spleen Qi Deficiency Syndrome",[34,35,36,37,38,39,40,71,42,43],"Qiling Yiqi Tablets",{"date":47,"type":48},{"date":50,"type":22},{"date":52,"type":22},{"name":54,"class":55},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":56},"100638801","noninvasive-early-diagnosis-of-colorectal-cancer-using-odor-targeted-capture-point-of-care-testing-and-intelligent-analysis-100638801","NCT07620743","Noninvasive Early Diagnosis of Colorectal Cancer Using Odor-Targeted Capture, Point-of-Care Testing, and Intelligent Analysis","Key Technology Research on Non-invasive Early Diagnosis of Colorectal Cancer Based on Odor-targeted Capture, Instant Detection, and Intelligent Analysis","Inclusion Criteria:\n\n* Age 18 to 85 years, male or female\n* Histopathologically or cytologically confirmed colon or rectal cancer (TNM stage I-IV) for colorectal cancer group\n* Histopathologically confirmed adenomatous polyps, sessile serrated lesions, traditional serrated adenomas, or other precancerous lesions for precancerous lesion group\n* No abnormality on colonoscopy within the past year; no personal history of colorectal cancer or other malignancies; no chronic diseases requiring long-term treatment for healthy control group\n* Willing and able to provide signed informed consent\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer syndromes (e.g., familial adenomatous polyposis, hereditary non-polyposis colorectal cancer)\n* Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis)\n* Severe cardiovascular, respiratory, or urinary system diseases\n* Other primary malignant tumors\n* Hematological diseases\n* Unable to comply with study procedures (e.g., sample collection or questionnaires)\n* Planning to become pregnant, pregnant, or breastfeeding\n* Suspected or confirmed alcohol or drug abuse\n* Known allergy to any drug used for colorectal cancer treatment\n* Participation in another interventional drug clinical trial within the past month\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study",true,"85 Years",{"count":86,"type":22},453,"OBSERVATIONAL","The goal of this observational study is to see whether a new, noninvasive test that analyzes smells (odor) from breath and intestinal gas can help detect colorectal cancer and precancerous growths at an early stage.\n\nThe main questions it aims to answer are:\n\nCan the new odor-based test correctly identify people who have colorectal cancer or precancerous lesions?\n\nHow accurate is the new test compared to the current standard method (colonoscopy with biopsy)?\n\nResearchers will compare the results of the new test with standard diagnostic results.\n\nParticipants will be asked to:\n\nProvide samples of breath, urine, stool, and intestinal gas (collected using a special device or a collection bag)\n\nAllow researchers to review their medical records and colonoscopy results\n\nAnswer questions about their health history and lifestyle\n\nThis study involves no treatments or procedures beyond normal medical care. It only collects samples and data for research purposes.",[90,91,92],"CRC","Precancerous Condition","Healthy","2026-05-29",{"date":95,"type":48},"2026-06-02",{"date":97,"type":22},"2026-06-10",{"date":99,"type":22},"2029-12-31",{"name":54,"class":55},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":56},"100591454","phase-4-a-trial-of-shengmai-liquid-for-long-covid-fatigue-100591454","NCT06980636","A Trial of Shengmai Liquid for Long COVID Fatigue.","Shengmai Liquid for Long COVID Fatigue: a Randomized Placebo-controlled Trial.","Shengmai LOFT","Inclusion Criteria:\n\n* Aged between 18 and 75 years;\n* Meet the above diagnostic criteria;\n* Meet the traditional Chinese medicine syndrome diagnostic criteria;\n* Consent and sign the informed consent form\n\nExclusion Criteria:\n\n* Currently in need of or expected to require high-flow oxygen therapy, positive pressure ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) and other advanced respiratory support measures;\n* Have a known history of active liver disease (excluding non-alcoholic fatty liver changes), including active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh class B or C liver function impairment, or acute liver failure. Liver function at screening shows any of the following: serum alanine aminotransferase (ALT) \\>3× the upper limit of normal (ULN); serum aspartate aminotransferase (AST) \\>3×ULN; serum bilirubin \\>2×ULN;\n* Undergoing dialysis treatment, or known to have moderate to severe renal impairment (i.e., an estimated glomerular filtration rate (eGFR) value calculated based on serum creatinine using the CKD-EPI formula ≤45 mL\u002Fmin\u002F1.73 m² within 6 months before screening);\n* Moderate to severe congestive heart failure within 6 months before screening (according to the New York Heart Association classification criteria, with cardiac function class III or IV), experienced a stroke, myocardial infarction, or coronary artery stent implantation; or have uncontrolled hypertension (defined as systolic blood pressure exceeding 160 mmHg or diastolic blood pressure exceeding 100 mmHg, with relevant records). Significant or clinically relevant electrocardiogram abnormalities, such as second-degree type II atrioventricular block, left bundle branch block, etc.;\n* Suffered from influenza A, influenza B, or other infectious diseases within 3 months before screening;\n* Have\u002Fever had severe neurological diseases (epilepsy, convulsions, or seizures) or mental illness, or have a family history of mental illness;\n* Pregnant or breastfeeding. Women who are breastfeeding or have a positive pregnancy test before taking the medication;\n* History of malignant tumors within 5 years before screening, with existing and progressing tumors, and patients who are expected to need treatment during the study period;\n* Have chronic fatigue syndrome or autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.);\n* Known allergy to any component of the study drug;\n* Diseases judged by the investigator to be unsuitable for participation in this study;\n* Taken traditional Chinese medicine containing Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, or Astragalus membranaceus within 2 weeks before screening;\n* Participating in other drug or medical device-related studies at the same time","75 Years",{"count":111,"type":22},100,[113],"PHASE4","The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid. The main questions it aims to answer are:\n\n* Dose the Shengmai liquid will reduce the level of fatigue in the participants and reduce the fatigue scale score of the participants?\n* Dose the Shengmai liquid will reduce the level of anxiety and depression in the participants and improve the sleep quality and quality of life of the participants Researchers will compare Shengmai oral liquid to a placebo (a look-alike substance that contains no drug) to see if Shengmai liquid works to treat Long Covid fatigue.\n\nParticipants will:\n\n* Take Shengmai liquid or a placebo every day for 8 weeks.\n* Visit the clinic once every 4 weeks for check up and test. There are a total of two telephone follow-ups, one follow-up 15 days after the treatment starts and another follow-up 30 days after the treatment ends.\n* Participants' medication responses and scale scores will be recorded.",[116],"Long COVID Fatigue","RECRUITING","2026-02-05",{"date":120,"type":48},"2026-02-09",{"date":122,"type":48},"2025-12-01",{"date":124,"type":22},"2026-11-30",{"name":54,"class":55},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":133,"targetDuration":135,"studyType":87,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100305877","risk-assessment-and-syndrome-evolution-models-for-chronic-atrophic-gastritis-malignant-transformation-100305877","NCT03261934","Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation","Risk Assessment and Syndrome Evolution Models Combining Traditional Chinese Medicine and Modern Medicine Indicators for Chronic Atrophic Gastritis Malignant Transformation: a Registry Study","Inclusion Criteria:\n\n(1) 18-75 years of age; (2) Meeting diagnostic criteria of CAG after upper gastrointestinal endoscopy; (3) Willing to cooperate with data, tissue sample, and blood sample collection during recruitment; (4) Willing to respond truthfully and timely to researcher queries after recruitment, able to cooperate with data, tissue sample and blood sample collection during follow-ups; (5) Willing to sign informed consent.\n\nExclusion Criteria:\n\n(1) Meeting past history of previous stomach surgery; (2) Unable to participate in data, tissue sample or blood sample collection for any reason.",{"count":134,"type":22},2000,"10 Years","Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to developed risk assessment and syndrome evolution models of CAG malignant transformation events combining TCM indicators with modern medicine indicators. The proposed study is a registry study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 study patients diagnosed with CAG will be recruited. 10-year follow-ups are carried out on-site in hospitals and off-site by telephone to track malignant transformation events.",[138],"Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation",[140,141,142,143,40,144],"Chronic Atrophic Gastritis","Malignant Transformation","Risk Assessment","Syndrome Evolution","Registry Study","2020-12-25",{"date":147,"type":48},"2020-12-29",{"date":149,"type":48},"2018-01-01",{"date":151,"type":22},"2030-12-31",{"name":54,"class":55},2,""]